scholarly journals Radiation Therapy Combined with Cowpea Mosaic Virus Nanoparticle in Situ Vaccination Initiates Immune-Mediated Tumor Regression

ACS Omega ◽  
2018 ◽  
Vol 3 (4) ◽  
pp. 3702-3707 ◽  
Author(s):  
Ravi Patel ◽  
Anna E. Czapar ◽  
Steven Fiering ◽  
Nancy L. Oleinick ◽  
Nicole F. Steinmetz
Keyword(s):  
Radiation Therapy ◽  
Mosaic Virus ◽  
Tumor Regression ◽  
Cowpea Mosaic Virus ◽  
Immune Mediated

scholarly journals Slow-Release Formulation of Cowpea Mosaic Virus for In Situ Vaccine Delivery to Treat Ovarian Cancer

2018 ◽  
Vol 5 (5) ◽  
pp. 1700991 ◽  
Author(s):  
Anna E. Czapar ◽  
Brylee David B. Tiu ◽  
Frank A. Veliz ◽  
Jonathan K. Pokorski ◽  
Nicole F. Steinmetz
Keyword(s):  
Ovarian Cancer ◽  
Mosaic Virus ◽  
Slow Release ◽  
Vaccine Delivery ◽  
Cowpea Mosaic Virus ◽  
Release Formulation ◽  
Slow Release Formulation ◽  
In Situ Vaccine

scholarly journals In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

2015 ◽  
Vol 11 (3) ◽  
pp. 295-303 ◽  
Author(s):  
P. H. Lizotte ◽  
A. M. Wen ◽  
M. R. Sheen ◽  
J. Fields ◽  
P. Rojanasopondist ◽  
...  
Keyword(s):  
Mosaic Virus ◽  
Metastatic Cancer ◽  
Cowpea Mosaic Virus

scholarly journals In situ vaccine application of inactivated CPMV nanoparticles for cancer immunotherapy

2021 ◽  
Author(s):  
Paul L. Chariou ◽  
Veronique Beiss ◽  
Yifeng Ma ◽  
Nicole F. Steinmetz
Keyword(s):  
Cancer Immunotherapy ◽  
Mosaic Virus ◽  
Biomedical Applications ◽  
Cowpea Mosaic Virus ◽  
Development Pipeline ◽  
In Situ Vaccine

Cowpea mosaic virus (CPMV) is currently in the development pipeline for multiple biomedical applications, including cancer immunotherapy.

scholarly journals IMMU-73. GLIOMA IN SITU VACCINATION WITH COWPEA MOSAIC VIRUS NANOPARTICLES

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi138-vi138
Author(s):  
Amber Kerstetter-Fogle ◽  
Sourabh Shukla ◽  
Veronique Beiss ◽  
Peggy Harris ◽  
Andrew Sloan ◽  
...  
Keyword(s):  
Mosaic Virus ◽  
Cowpea Mosaic Virus

scholarly journals Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties

2019 ◽  
Vol 93 (21) ◽  
Author(s):  
Chao Wang ◽  
Veronique Beiss ◽  
Nicole F. Steinmetz
Keyword(s):  
Mosaic Virus ◽  
Tumor Regression ◽  
Expression System ◽  
Plant Viruses ◽  
Cowpea Mosaic Virus ◽  
Wild Type ◽  
Virus Like Particles ◽  
Virus Rna ◽  
Tumor Mouse Model ◽  
Cell Expression

ABSTRACT Cowpea mosaic virus (CPMV) is a plant virus that has been developed for multiple biomedical and nanotechnology applications, including immunotherapy. Two key platforms are available: virus nanoparticles (VNPs) based on the complete CMPV virion, including the genomic RNA, and virus-like nanoparticles (VLPs) based on the empty CPMV (eCPMV) virion. It is unclear whether these platforms differ in terms of immunotherapeutic potential. We therefore compared their physicochemical properties and immunomodulatory activities following in situ vaccination of an aggressive ovarian tumor mouse model (ID8-Defb29/Vegf-A). In physicochemical terms, CPMV and eCPMV were very similar, and both significantly increased the survival of tumor-bearing mice and showed promising antitumor efficacy. However, they demonstrated distinct yet overlapping immunostimulatory effects due to the presence of virus RNA in wild-type particles, indicating their suitability for different immunotherapeutic strategies. Specifically, we found that the formulations had similar effects on most secreted cytokines and immune cells, but the RNA-containing CPMV particles were uniquely able to boost populations of potent antigen-presenting cells, such as tumor-infiltrating neutrophils and activated dendritic cells. Our results will facilitate the development of CPMV and eCPMV as immunotherapeutic vaccine platforms with tailored responses. IMPORTANCE The engagement of antiviral effector responses caused by viral infection is essential when using viruses or virus-like particles (VLPs) as an immunotherapeutic agent. Here, we compare the chemophysical and immunostimulatory properties of wild-type cowpea mosaic virus (CPMV) (RNA containing) and eCPMV (RNA-free VLPs) produced from two expression systems (agrobacterium-based plant expression system and baculovirus-insect cell expression). CPMV and eCPMV could each be developed as novel adjuvants to overcome immunosuppression and thus promote tumor regression in ovarian cancer (and other tumor types). To our knowledge, this is the first study to define the immunotherapeutic differences between CPMV and eCPMV, which is essential for the further development of biomedical applications for plant viruses and the selection of rational combinations of immunomodulatory reagents.

scholarly journals The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine

2020 ◽  
Vol 8 (19) ◽  
pp. 5489-5503
Author(s):  
Sourabh Shukla ◽  
Chao Wang ◽  
Veronique Beiss ◽  
Hui Cai ◽  
Torus Washington ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Mosaic Virus ◽  
Cancer Vaccine ◽  
Cowpea Mosaic Virus ◽  
Icosahedral Viruses ◽  
Viral Nanoparticle

Plant viral nanoparticle CPMV outperforms other icosahedral viruses as an in situ vaccine for cancer immunotherapy.

scholarly journals SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ye Wang ◽  
Morvarid Mohseni ◽  
Angelo Grauel ◽  
Javier Estrada Diez ◽  
Wei Guan ◽  
...  
Keyword(s):  
T Cell ◽  
Tumor Immunity ◽  
Immune Cell ◽  
Tumor Regression ◽  
Tyrosine Phosphatase ◽  
Cytotoxic T Cell ◽  
Cell Recruitment ◽  
Inhibitory Function ◽  
Immune Mediated ◽  
Cytotoxic Function

AbstractSHP2 is a ubiquitous tyrosine phosphatase involved in regulating both tumor and immune cell signaling. In this study, we discovered a novel immune modulatory function of SHP2. Targeting this protein with allosteric SHP2 inhibitors promoted anti-tumor immunity, including enhancing T cell cytotoxic function and immune-mediated tumor regression. Knockout of SHP2 using CRISPR/Cas9 gene editing showed that targeting SHP2 in cancer cells contributes to this immune response. Inhibition of SHP2 activity augmented tumor intrinsic IFNγ signaling resulting in enhanced chemoattractant cytokine release and cytotoxic T cell recruitment, as well as increased expression of MHC Class I and PD-L1 on the cancer cell surface. Furthermore, SHP2 inhibition diminished the differentiation and inhibitory function of immune suppressive myeloid cells in the tumor microenvironment. SHP2 inhibition enhanced responses to anti-PD-1 blockade in syngeneic mouse models. Overall, our study reveals novel functions of SHP2 in tumor immunity and proposes that targeting SHP2 is a promising strategy for cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document